EluPro™ Achieves Prestigious 2025 Edison Award Recognition
An Innovative Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Pacemakers and Neurostimulators Earns Bronze in Post-Surgical Recovery Solutions Category
It’s a moment of pride for Elutia Inc. As a frontrunner in drug-eluting biomatrix technologies, the company has just received a prestigious honor; EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope, was awarded the 2025 Bronze Edison Award™. This award brings an esteemed recognition to a product that focuses on diminishing postoperative complications associated with cardiac implants like pacemakers and neurostimulators.
Mentioning the achievement, Dr. Randy Mills, the CEO of Elutia Inc., shared, "This award is not merely a title; it represents our unwavering dedication to resolving authentic challenges for individuals reliant on these technologies. The relentless efforts put forth by the Elutia team allow patients across the globe to experience quality health without compromise. I want to congratulate each member of our team for their remarkable efforts!"
Since its launch in January 2025, EluPro has been cleared for use with a variety of cardiac implanted electronic device (CIED) products, which include pacemakers and implantable defibrillators. What sets EluPro apart from traditional synthetic alternatives is its unique formulation that integrates a soft, regenerative biomatrix with the well-researched antibiotics rifampin and minocycline. This innovative approach targets complications that can arise from CIEDs, encouraging optimal healing and recovery.
Every year, over 600,000 CIEDs are implanted in the U.S. alone, with a notable percentage of patients facing post-surgical complications like infections and device migration. This statistic highlights the pressing demand for effective solutions in the medical community. EluPro addresses these issues head-on, offering patients and healthcare providers a dependable solution for enhancing patient outcomes following surgery.
EluPro was recognized at the 2025 Edison Awards ceremony, held at the Luminary Hotel along with the Caloosa Sound Convention Center. This annual event celebrates groundbreaking innovations and brings together a diverse group of thought leaders and innovators.
Discover More About Elutia
Elutia Inc. is dedicated to advancing the capabilities of drug-eluting biomatrix technology, aiming to foster a better connection between medical devices and the patients they serve. As the demand for implantable technologies continues to rise, Elutia is committed to humanizing medicine, ensuring that patients are cared for with the utmost consideration. To learn more about EluPro and other innovative offerings, visit www.elutia.com/products/elupro/.
Understanding the Edison Awards
Founded in 1987, the Edison Awards honor a wide spectrum of innovations and innovators. Named after the well-known inventor Thomas Edison, these accolades celebrate excellence in the development of new products, services, marketing initiatives, and design. They serve as a beacon for those striving to innovate and make a significant impact within their industries.
Frequently Asked Questions
What is EluPro™?
EluPro™ is an FDA-cleared antibiotic-eluting bioenvelope designed to reduce complications post-surgery for patients with cardiac implanted electronic devices and neurostimulators.
What recognition did EluPro™ earn recently?
EluPro™ was awarded the 2025 Bronze Edison Award™ for its innovative approach in the healthcare industry.
Who is the CEO of Elutia Inc.?
Dr. Randy Mills serves as the CEO of Elutia Inc. and has expressed pride in the company's achievements.
How does EluPro™ differ from traditional solutions?
EluPro™ incorporates a regenerative biomatrix combined with antibiotics to address complications resulting from CIEDs, fostering better healing outcomes compared to synthetic alternatives.
Where can I find more information about Elutia Inc.?
You can visit their website at www.elutia.com for more details about their products and initiatives.
